Acromegaly, IGF1 bioactivity, and S-Klotho
The value of measuring IGF1 bioactivity in active acromegaly is unknown. Soluble Klotho (S-Klotho) level is elevated in active acromegaly and it has been suggested that S-Klotho can inhibit activation of the IGF1 receptor (IGF1R). A cross-sectional study was carried out in 15 patients with active acromegaly, finding that IGF1 bioactivity was within the reference range in a considerable number of subjects with active acromegaly and that elevated S-Klotho levels may have reduced IGF1 bioactivity. Moreover, IGF1 bioactivity was more strongly related to physical measures of QoL than total IGF1, suggesting that IGF1 bioactivity may better reflect physical limitations perceived in active acromegaly. Read the full article at Varewijck et al. (2014) Endocrine Connections 3 85–92 http://dx.doi.org/10.1530/EC-14-0028
Condition: Acromegaly Interventions: Drug: ONO-5788; Drug: [14C]-ONO-5788 Sponsor: Ono Pharmaceutical Co. Ltd Not yet recruiting
ConclusionsPDP should be considered as a differential diagnosis when a patient presents with hypertrophic osteoarthropathy and acromegalic features.
Authors: Kan S, Kizilgul M, Celik B, Beysel S, Caliskan M, Apaydin M, Ucan B, Cakal E Abstract Nodular thyroid disease is a very common disorder in patients with acromegaly. Insulin-like growth factor-1 (IGF-1) is a thyroid growth factor, and there is a correlation between IGF-1 levels and thyroid volume (TV) in patients with acromegaly. There is no study investigating the impact of somatostatin analog (SSA) treatment on thyroid nodule volume in patients with acromegaly. We aimed to assess thyroid nodule volume change with SSA treatment in patients with persistent acromegaly. We retrospectively analyzed data from 1...
ConclusionsPatient adherence to pegvisomant was high (60.7 –92.1%), but more than a third of the patients in the study made mistakes during the administration process, with a potential impact on disease control. Besides dosing compliance, correct administration of medication should be carefully assessed in these patients.
Publication date: Available online 10 February 2019Source: Molecular Phylogenetics and EvolutionAuthor(s): Michael Knapp, Jessica E. Thomas, James Haile, Stefan Prost, Simon Y.W. Ho, Nicolas Dussex, Sophia Cameron-Christie, Olga Kardailsky, Ross Barnett, Michael Bunce, M. Thomas P. Gilbert, R. Paul ScofieldAbstractPrior to human arrival in the 13th century, two large birds of prey were the top predators in New Zealand. In the absence of non-volant mammals, the extinct Haast's eagle (Hieraaetus moorei), the largest eagle in the world, and the extinct Eyles' harrier (Circus teauteensis) the largest harrier in the world, had ...
CONCLUSIONS: Coexistence of acromegaly and numerous other tumors suggests a common etiology of these disorders. However, no genetic abnormality could be identified with the tests that have been performed. PMID: 30742299 [PubMed - as supplied by publisher]
Authors: Pico A Abstract PMID: 30732428 [PubMed - as supplied by publisher]
Presenting an integrated case discussion on acromegaly in DAMS Unplugged series.Famous Radiology Blog http://www.sumerdoc.blogspot.com TeleRad Providers at www.teleradproviders.com Mail us at email@example.com
aù F Abstract The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). Medical therapy is generally life-long in patients with acromegaly, since disease remission is very uncommon after SSA discontinuation and has never been reported after PEG withdrawal. Here, we report for the first time the cases of two acromegaly patients treated with PEG monotherapy for many years because of resistance to SSA, who persistently maintained normal serum IGF-1 levels after PEG withdrawal. The first patie...